Ralph T Schermuly

List of Publications by Year in Descending Order

188 papers	12,103 citations	55 h-index	106 g-index
206 ext. papers	14,193 ext. citations	8.5 avg, IF	5.81 L-index

#	Paper	IF	Citations
188	The effect of long-term doxycycline treatment in a mouse model of cigarette smoke-induced emphysema and pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2021**, 320, L903-L915	5.8	1
187	Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2021**, 64, 100-114	5.7	10
186	The role of chemokines and chemokine receptors in pulmonary arterial hypertension. *British Journal of Pharmacology*, **2021**, 178, 72-89	8.6	23
185	Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. *British Journal of Pharmacology*, **2021**, 178, 31-53	8.6	5
184	Genetic Delivery and Gene Therapy in Pulmonary Hypertension. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
183	Experimental Models **2021**, 27-52		
182	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	7
181	Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model. *International Journal of Environmental Research and Public Health* , **2021**, 18,	4.6	1
180	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. *Communications Biology*, **2021**, 4, 1002	6.7	
179	Generation of pulmonary arterial hypertension patient-specific induced pluripotent stem cell lines from three unrelated patients with a heterozygous missense mutation in exon 12, a heterozygous in-frame deletion in exon 3 and a missense mutation in exon 11 of the BMPR2 gene. *Stem Cell Research*, **2021**, 55, 102488	1.6	0
178	Lack of Contribution of p66shc to Pressure Overload-Induced Right Heart Hypertrophy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
177	Effect of p53 activation on experimental right ventricular hypertrophy. *PLoS ONE*, **2020**, 15, e0234872	3.7	2
176	Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice. *Respiratory Research*, **2020**, 21, 136	7.3	4
175	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. *Nature Metabolism*, **2020**, 2, 532-546	14.6	4
174	Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. *Acta Physiologica*, **2020**, 230, e13521	5.6	4
173	is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties. *Medicina (Lithuania)*, **2020**, 56,	3.1	1
172	Profiling of human lymphocytes reveals a specific network of protein kinases modulated by endurance training status. *Scientific Reports*, **2020**, 10, 888	4.9	9

171	Lung epithelium damage in COPD - An unstoppable pathological event?. *Cellular Signalling*, **2020**, 68, 109540	4.9	9
170	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. *Basic Research in Cardiology*, **2020**, 115, 17	11.8	14
169	IRAG1 Deficient Mice Develop PKG1Dependent Pulmonary Hypertension. *Cells*, **2020**, 9,	7.9	2
168	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. *Pulmonary Circulation*, **2020**, 10, 2045894020947283	2.7	2
167	Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
166	Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. *Science Advances*, **2020**, 6, eaba0694	14.3	18
165	Update in Pulmonary Vascular Diseases and Right Ventricular Dysfunction 2019. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 22-28	10.2	3
164	Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1550-1554	10.2	2
163	Pulmonary Vascular Pressure Response to Acute Cold Exposure in Kyrgyz Highlanders. *High Altitude Medicine and Biology*, **2019**, 20, 375-382	1.9	2
162	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. *Nature Communications*, **2019**, 10, 2204	17.4	39
161	Lipids - two sides of the same coin in lung fibrosis. *Cellular Signalling*, **2019**, 60, 65-80	4.9	8
160	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. *Frontiers in Physiology*, **2019**, 10, 54	4.6	3
159	LRP1 promotes synthetic phenotype of pulmonary artery smooth muscle cells in pulmonary hypertension. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 1604-1616	6.9	10
158	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. *European Respiratory Journal*, **2019**, 53,	13.6	15
157	Reply to Bogaard : Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1450-1452	10.2	4
156	Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. *Nature Communications*, **2019**, 10, 2987	17.4	89
155	Depletion of Bone Marrow-Derived Fibrocytes Attenuates TAA-Induced Liver Fibrosis in Mice. *Cells*, **2019**, 8,	7.9	9
154	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1407-1420	10.2	25

153	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *European Respiratory Journal*, **2019**, 53,	13.6	407
152	Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis. *American Journal of Respiratory Cell and Molecular Biology*, **2019**, 60, 346-356	5.7	14
151	Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. *European Respiratory Journal*, **2018**,	13.6	30
150	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. *BMC Pulmonary Medicine*, **2018**, 18, 41	3.5	31
149	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 373-385	10.2	57
148	Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. *Frontiers in Physiology*, **2018**, 9, 609	4.6	26
147	Is the fibroblast growth factor signaling pathway a victim of receptor tyrosine kinase inhibition in pulmonary parenchymal and vascular remodeling?. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2018**, 315, L248-L252	5.8	8
146	Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase. *JCI Insight*, **2018**, 3,	9.9	25
145	Response to: Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding". *BioMed Research International*, **2018**, 2018, 7491284	3	
144	The Role of G Protein-Coupled Receptors in the Right Ventricle in Pulmonary Hypertension. *Frontiers in Cardiovascular Medicine*, **2018**, 5, 179	5.4	6
143	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. *Circulation: Cardiovascular Imaging*, **2018**, 11, e007653	3.9	5
142	Nintedanib in Severe Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 808-810	10.2	11
141	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. *BioMed Research International*, **2018**, 2018, 3293584	3	17
140	Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. *Experimental Physiology*, **2018**, 103, 1185-1191	2.4	7
139	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. *Chest*, **2017**, 151, 468-480	5.9	57
138	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. *Journal of Heart and Lung Transplantation*, **2017**, 36, 957-967	5.8	138
137	Amplified canonical transforming growth factor-β signalling heat shock protein 90 in pulmonary fibrosis. *European Respiratory Journal*, **2017**, 49,	13.6	43
136	Enhanced inflammatory cell profiles in schistosomiasis-induced pulmonary vascular remodeling. *Pulmonary Circulation*, **2017**, 7, 244-252	2.7	5

135	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. *Circulation Research*, **2017**, 121, 424-438	15.7	58
134	Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. *Lung*, **2017**, 195, 489-496	2.9	10
133	Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. *Circulation*, **2017**, 136, 65-79	16.7	145
132	Oxidative injury of the pulmonary circulation in the perinatal period: Short- and long-term consequences for the human cardiopulmonary system. *Pulmonary Circulation*, **2017**, 7, 55-66	2.7	17
131	Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. *Experimental Physiology*, **2017**, 102, 180-189	2.4	14
130	Differential Alterations of the Mitochondrial Morphology and Respiratory Chain Complexes during Postnatal Development of the Mouse Lung. *Oxidative Medicine and Cellular Longevity*, **2017**, 2017, 9169146	6.7	11
129	Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4). *PLoS ONE*, **2017**, 12, e0183166	3.7	17
128	Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. *Physiological Reports*, **2017**, 5, e13146	2.6	30
127	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. *Science Translational Medicine*, **2017**, 9,	17.5	50
126	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. *American Journal of Respiratory Cell and Molecular Biology*, **2017**, 57, 603-614	5.7	48
125	Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. *Cell Stem Cell*, **2017**, 20, 261-273.e3	18	118
124	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 583-595	10.2	95
123	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. *Oncotarget*, **2017**, 8, 29613-29624	3.3	6
122	The prognostic impact of thyroid function in pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2016**, 35, 1427-1434	5.8	14
121	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. *International Journal of Cardiology*, **2016**, 216, 85-91	3.2	20
120	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2016**, 12, 63-8	6	13
119	miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. *Cardiovascular Research*, **2016**, 111, 184-93	9.9	42
118	Endothelial actions of atrial natriuretic peptide prevent pulmonary hypertension in mice. *Basic Research in Cardiology*, **2016**, 111, 22	11.8	12

117	Nestin-expressing vascular wall cells drive development of pulmonary hypertension. *European Respiratory Journal*, **2016**, 47, 876-88	13.6	24
116	Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. *PLoS ONE*, **2016**, 11, e0165982	3.7	5
115	Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy. *Pulmonary Circulation*, **2016**, 6, 516-523	2.7	5
114	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1137-1149	13.6	57
113	Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 1236-45	9.4	31
112	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. *European Respiratory Journal*, **2015**, 46, 1084-94	13.6	29
111	Loss of secreted frizzled-related protein-1 leads to deterioration of cardiac function in mice and plays a role in human cardiomyopathy. *Circulation: Heart Failure*, **2015**, 8, 362-72	7.6	43
110	New potential diagnostic biomarkers for pulmonary hypertension. *European Respiratory Journal*, **2015**, 46, 1390-6	13.6	22
109	The F-BAR Protein NOSTRIN Dictates the Localization of the Muscarinic M3 Receptor and Regulates Cardiovascular Function. *Circulation Research*, **2015**, 117, 460-9	15.7	11
108	5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. *BioMed Research International*, **2015**, 2015, 438403	3	48
107	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. *PLoS ONE*, **2015**, 10, e0129327	3.7	24
106	Impact of S-adenosylmethionine decarboxylase 1 on pulmonary vascular remodeling. *Circulation*, **2014**, 129, 1510-23	16.7	17
105	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. *Nature Medicine*, **2014**, 20, 1289-300	50.5	183
104	Endothelin-1 driven proliferation of pulmonary arterial smooth muscle cells is c-fos dependent. *International Journal of Biochemistry and Cell Biology*, **2014**, 54, 137-48	5.6	34
103	Protective effects of 10-nitro-oleic acid in a hypoxia-induced murine model of pulmonary hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2014**, 51, 155-62	5.7	45
102	Novel and emerging therapies for pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 394-400	10.2	62
101	Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1 depletion or imatinib treatment. *Thrombosis and Haemostasis*, **2014**, 112, 1288-303	7	15
100	Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease. *Pulmonary Circulation*, **2014**, 4, 128-36	2.7	26

99	Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 1359-73	10.2	59
98	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2014**, 306, L986-95	5.8	25
97	Experimental Models **2014**, 45-67		
96	Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model. *American Journal of Respiratory Cell and Molecular Biology*, **2013**, 49, 358-67	5.7	50
95	Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. *Basic Research in Cardiology*, **2013**, 108, 325	11.8	54
94	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. *International Journal of Cardiology*, **2013**, 167, 2630-7	3.2	29
93	Relevant issues in the pathology and pathobiology of pulmonary hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D4-12	15.1	379
92	Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. *Antioxidants and Redox Signaling*, **2013**, 19, 2213-31	8.4	57
91	The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. *Journal of Pathology*, **2013**, 229, 242-9	9.4	29
90	Cofilin, a hypoxia-regulated protein in murine lungs identified by 2DE: role of the cytoskeletal protein cofilin in pulmonary hypertension. *Proteomics*, **2013**, 13, 75-88	4.8	14
89	Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: role of transmembrane SCF and the PAR-2/PKC-/Raf-1/p44/42 signaling pathway. *American Journal of Pathology*, **2013**, 182, 2094-108	5.8	69
88	Inhibition of overactive transforming growth factor- signaling by prostacyclin analogs in pulmonary arterial hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2013**, 48, 733-41	5.7	35
87	Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 1451-9	10.2	58
86	Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. *Pulmonary Circulation*, **2013**, 3, 226-44	2.7	35
85	The peroxisome proliferator-activated receptor /agonist GW0742 has direct protective effects on right heart hypertrophy. *Pulmonary Circulation*, **2013**, 3, 926-35	2.7	18
84	Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology* , **2013**, 33, 34-42	9.4	55
83	A molecular mechanism for therapeutic effects of cGMP-elevating agents in pulmonary arterial hypertension. *Journal of Biological Chemistry*, **2013**, 288, 16557-16566	5.4	20
82	The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. *Experimental Physiology*, **2013**, 98, 1274-8	2.4	9

81	Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. *Histology and Histopathology*, **2013**, 28, 691-9	1.4	13
80	Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not. *Molecular and Cellular Endocrinology*, **2012**, 349, 145-53	4.4	11
79	Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 897-908	10.2	219
78	BDNF/TrkB signaling augments smooth muscle cell proliferation in pulmonary hypertension. *American Journal of Pathology*, **2012**, 181, 2018-29	5.8	35
77	Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. *Nature Communications*, **2012**, 3, 649	17.4	137
76	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. *PLoS ONE*, **2012**, 7, e43433	3.7	89
75	Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. *Free Radical Biology and Medicine*, **2012**, 52, 1033-42	7.8	60
74	Role of Src tyrosine kinases in experimental pulmonary hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 1354-65	9.4	90
73	Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 409-19	10.2	171
72	PAR-2 inhibition reverses experimental pulmonary hypertension. *Circulation Research*, **2012**, 110, 1179-91	15.7	52
71	Mitochondrial complex II is essential for hypoxia-induced pulmonary vasoconstriction of intra- but not of pre-acinar arteries. *Cardiovascular Research*, **2012**, 93, 702-10	9.9	16
70	Riociguat for the treatment of pulmonary hypertension. *Expert Opinion on Investigational Drugs*, **2011**, 20, 567-76	5.9	69
69	Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. *Cell*, **2011**, 147, 293-305	56.2	226
68	Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. *PLoS ONE*, **2011**, 6, e18136	3.7	30
67	Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. *Respiratory Research*, **2011**, 12, 60	7.3	53
66	Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. *Respiratory Research*, **2011**, 12, 87	7.3	16
65	Mechanisms of disease: pulmonary arterial hypertension. *Nature Reviews Cardiology*, **2011**, 8, 443-55	14.8	472
64	Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1092-102	10.2	64

63	cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. *Circulation*, **2011**, 123, 1194-204	16.7	34
62	Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-*Pulmonary Circulation*, **2011**, 1, 259-68	2.7	38
61	The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. *Science Translational Medicine*, **2011**, 3, 87ra53	17.5	50
60	A role for coagulation factor Xa in experimental pulmonary arterial hypertension. *Cardiovascular Research*, **2011**, 92, 159-68	9.9	26
59	Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. *PLoS ONE*, **2011**, 6, e18883	3.7	33
58	Targeting non-malignant disorders with tyrosine kinase inhibitors. *Nature Reviews Drug Discovery*, **2010**, 9, 956-70	64.1	102
57	Role of epidermal growth factor inhibition in experimental pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 158-67	10.2	99
56	Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 279-88	10.2	93
55	Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 805-18	10.2	54
54	Animal models of pulmonary hypertension: role in translational research. *Drug Discovery Today: Disease Models*, **2010**, 7, 89-97	1.3	8
53	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. *Respiratory Research*, **2010**, 11, 146	7.3	17
52	Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. *Journal of Molecular and Cellular Cardiology*, **2010**, 49, 598-605	5.8	47
51	PDGF receptor and its antagonists: role in treatment of PAH. *Advances in Experimental Medicine and Biology*, **2010**, 661, 435-46	3.6	47
50	Targeting cancer with phosphodiesterase inhibitors. *Expert Opinion on Investigational Drugs*, **2010**, 19, 117-31	5.9	105
49	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. *BMC Pulmonary Medicine*, **2010**, 10, 26	3.5	29
48	Heme oxygenase-2 and large-conductance Ca2+-activated K+ channels: lung vascular effects of hypoxia. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 353-64	10.2	34
47	The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2009**, 40, 683-91	5.7	80
46	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2009**, 297, L658-65	5.8	32

45	Inflammation, growth factors, and pulmonary vascular remodeling. *Journal of the American College of Cardiology*, **2009**, 54, S10-S19	15.1	518
44	Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. *Journal of Hypertension*, **2009**, 27, 322-31	1.9	50
43	Fhl-1, a new key protein in pulmonary hypertension. *Circulation*, **2008**, 118, 1183-94	16.7	71
42	Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. *Circulation*, **2008**, 118, 2081-90	16.7	121
41	Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 188-96	10.2	66
40	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. *BMC Pulmonary Medicine*, **2008**, 8, 25	3.5	31
39	Dysregulated bone morphogenetic protein signaling in monocrotaline-induced pulmonary arterial hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 1072-8	9.4	115
38	Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. *Respiratory Research*, **2007**, 8, 4	7.3	31
37	Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension. *Circulation*, **2007**, 115, 2957-68	16.7	43
36	Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. *Circulation Research*, **2007**, 101, 258-67	15.7	279
35	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. *Circulation*, **2007**, 115, 2331-9	16.7	118
34	Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide. *Respiratory Medicine*, **2007**, 101, 2125-32	4.6	24
33	In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase. *Journal of Pharmacology and Experimental Therapeutics*, **2006**, 317, 181-7	4.7	11
32	Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. *Circulation*, **2006**, 113, 286-95	16.7	183
31	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 19093-8	11.5	247
30	Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2006**, 19, 353-63		13
29	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. *Thrombosis and Haemostasis*, **2006**, 95, 720-727	7	20
28	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. *Respiratory Research*, **2005**, 6, 128	7.3	29

27	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. *Respiratory Research*, **2005**, 6, 76	7.3	25
26	Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. *Respiratory Research*, **2005**, 6, 86	7.3	27
25	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. *FASEB Journal*, **2005**, 19, 1175-7	0.9	144
24	Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 358-63	10.2	55
23	Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. *Current Topics in Developmental Biology*, **2005**, 67, 251-84	5.3	8
22	Reversal of experimental pulmonary hypertension by PDGF inhibition. *Journal of Clinical Investigation*, **2005**, 115, 2811-21	15.9	764
21	Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 39-45	10.2	207
20	Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. *Circulation Research*, **2004**, 94, 1101-8	15.7	86
19	Prostacyclin and its analogues in the treatment of pulmonary hypertension **2004**, 102, 139-53		102
18	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. *Journal of the American College of Cardiology*, **2004**, 44, 1488-96	15.1	86
17	Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 284, H931-8	5.2	29
16	Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1139-41	10.2	211
15	Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 168, 1358-65	10.2	150
14	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2003**, 42, 158-64	15.1	290
13	Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 741-5	4.7	20
12	Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. *Annals of Internal Medicine*, **2002**, 136, 515-22	8	346
11	Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. *Critical Care Medicine*, **2002**, 30, 2489-92	1.4	62
10	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. *Lancet, The*, **2002**, 360, 895-900	40	590

9	Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. *American Journal of Respiratory Cell and Molecular Biology*, **2001**, 25, 219-25	5.7	20
8	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L638-45	5.8	53
7	Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L792-800	5.8	15
6	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L896-904	5.8	19
5	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 281, L1361-8	5.8	30
4	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)?. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2000**, 279, L683-90	5.8	75
3	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **1999**, 276, L90-5	5.8	33
2	Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **1999**, 160, 600-7	10.2	300
1	Hypoxic Pulmonary Vasoconstriction Triggered by an Increase in Reactive Oxygen Species?. *Novartis Foundation Symposium*,196-213		8